Stock listing

NASDAQ:LIMN Liminatus Pharma, Inc. Stock

Home listing (NASDAQ) of Liminatus Pharma, Inc.

Follow Liminatus Pharma, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:LIMN

$2.51 USD -0.17 (-6.3%)

Close on Nov 20, 2026

Past year -95.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$2.51 – $2.99 USDNov 20, 2026
Volume
61,860 sharesNov 20, 2026
Market cap
$3.37M USDAt the close on Nov 20, 2026 · price × 1.34M shares outstanding
52-week range
$2.40 – $141.50 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$112,830 USDMedian day 23,146 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Liminatus Pharma, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:LIMN · Home$2.51 USD-0.17 (-6.3%)61,860$2.869$2.985$2.51$2.68Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:LIMN · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$2.51-0.17-6.3%$2.869$2.985$2.5161,860
$2.68-0.13-4.6%$2.90$2.94$2.6823,146
$2.81-0.16-5.4%$2.98$3.05$2.8022,764
$2.97-0.02-0.7%$3.125$3.13$2.9231,568
$2.99+0.22+7.9%$2.907$2.99$2.80513,223
$2.77-0.17-5.8%$3.04$3.04$2.779,902
$2.94+0.17+6.1%$2.979$3.075$2.8527,220
$2.77+0.06+2.2%$2.80$2.91$2.7619,358
$2.71+0.17+6.7%$2.56$2.825$2.5619,678
$2.54-0.09-3.4%$2.73$2.855$2.5031,621
$2.63-0.164-5.9%$2.91$3.07$2.60104,742
$2.794+0.004+0.2%$2.875$2.95$2.6633,652
$2.79+0.27+10.7%$2.63$2.83$2.40444,854
$2.52-0.30-10.6%$2.97$2.97$2.5223,274
$2.82-0.075-2.6%$2.98$3.00$2.7512,963
$2.895-0.025-0.9%$3.06$3.14$2.8128,056
$2.92+0.03+1.0%$3.106$3.106$2.9210,996
$2.89-0.27-8.5%$3.01$3.01$2.78524,113
$3.16+0.22+7.5%$3.05$3.245$2.969,366
$2.94-0.17-5.5%$3.10$3.17$2.90520,700
$3.11-0.01-0.3%$3.19$3.24$3.1012,800
$3.12-0.10-3.1%$3.26$3.455$3.04118,800
$3.22+0.11+3.5%$3.285$3.295$3.0533,000
$3.11+0.07+2.3%$3.175$3.285$3.0833,000
$3.04-0.17-5.3%$3.30$3.30$3.0117,100
$3.21-0.04-1.2%$3.295$3.364$3.2115,800
$3.25-0.16-4.7%$3.50$3.55$3.2520,100
$3.41-0.04-1.2%$3.625$3.625$3.4113,700
$3.45-0.31-8.2%$3.70$3.82$3.4028,800
$3.76+0.07+1.9%$3.555$3.81$3.55516,900
$3.69-0.19-4.9%$3.95$3.95$3.53138,600
$3.88+0.18+4.9%$3.701$3.89$3.6522,900
$3.70-0.29-7.3%$3.95$3.95$3.6912,500
$3.99+0.09+2.3%$3.80$4.08$3.8018,000
$3.90+0.15+4.0%$3.75$3.95$3.7524,300
$3.75+0.02+0.5%$3.74$3.86$3.6528,200
$3.73-0.18-4.6%$3.81$3.974$3.719,100
$3.91-0.36-8.4%$4.23$4.31$3.8338,400
$4.27+0.075+1.8%$4.14$4.479$4.1318,500
$4.195+0.015+0.4%$4.26$4.34$4.09117,700
$4.18+0.15+3.7%$4.16$4.23$4.0016,800
$4.03-0.04-1.0%$4.05$4.137$3.9017,200
$4.07+0.43+11.8%$3.71$4.26$3.64188,300
$3.64+0.16+4.6%$3.68$3.72$3.5616,000
$3.48+0.09+2.7%$3.43$3.675$3.4123,100
$3.39+0.06+1.8%$3.35$3.44$3.3458,900
$3.33-0.18-5.1%$3.46$3.545$3.3215,300
$3.51-0.01-0.3%$3.50$3.58$3.41514,000
$3.52+0.05+1.4%$3.45$3.615$3.2938,000
$3.47-0.16-4.4%$3.63$3.675$3.4631,400
$3.63+0.15+4.3%$3.54$3.80$3.45119,000
$3.48-0.14-3.9%$3.60$3.65$3.4820,800
$3.62-0.09-2.4%$3.72$3.725$3.5226,300
$3.71+0.01+0.3%$3.70$3.82$3.6523,200
$3.70-0.14-3.6%$3.64$3.91$3.6122,500
$3.84+0.195+5.3%$3.86$4.00$3.7031,600
$3.645-0.215-5.6%$3.80$3.80$3.4253,200
$3.86-0.37-8.7%$4.24$4.26$3.8051,300
$4.23-0.17-3.9%$4.36$4.74$4.2338,700
$4.40-0.01-0.2%$4.37$4.88$4.3751,800
$4.41-0.20-4.3%$4.42$4.545$4.2649,100
$4.61-0.06-1.3%$4.64$4.84$4.3573,212
$4.67-0.49-9.5%$5.03$5.04$4.6183,117
$5.16-0.47-8.3%$5.53$5.876$5.15117,361
$5.63+0.045+0.8%$5.69$5.945$5.3951,431

Splits

1 split · NASDAQ:LIMN · every price before a split is adjusted for it

DayRatioWhat
1-for-50Consolidation
Ticker
NASDAQ:LIMN
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Liminatus Pharma, Inc. news

Liminatus Pharma, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
8 in the last 12 months · 18 in all · newest Sep 29, 2026 · oldest 2022
Decks
1 deck · latest Jun 24, 2025

Where Liminatus Pharma, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:LIMN · Home listing · This pageNASDAQUnited StatesUSD
BOATS:LIMNBOATSUnited StatesUSD

Valuation

Price/book 11.2× against a median of 0.7×: the highest of 10 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$1.80M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
11.2×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
4.8×
Beta vs S&P 500
0.94

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Liminatus Pharma, Inc. · NASDAQ:LIMNUS$3.37MUS$1.80Mn/an/an/a11.2×n/a4.8×0.94
Biotron Limited · ASX:BITUS$3.69MUS$2.66Mn/an/an/a1.9×n/a0.0×n/a
Reviva Pharmaceuticals Holdings, Inc. · NASDAQ:RVPHUS$3.68M−US$13.77Mn/an/an/a0.3×n/a0.0×1.57
Xenetic Biosciences, Inc. · NASDAQ:XBIOUS$3.28M−US$2.53Mn/a−0.8×n/a0.7×−123.7%0.0×1.46
Aprea Therapeutics, Inc. · NASDAQ:APREUS$3.25M−US$34.60Mn/an/an/a0.1×n/a0.0×0.73
Spago Nanomedical AB · OMXSTO:SPAGOUS$3.20MUS$22,063n/a5.6×n/a1.0×n/a0.0×n/a
Kiora Pharmaceuticals, Inc. · NASDAQ:KPRXUS$3.19M−US$12.81Mn/a−12.8×n/a0.2×n/a0.0×1.54
Azitra Inc · AMEX:AZTRUS$3.13M−US$618,677n/an/an/a0.7×n/a0.0×0.60
NuCana plc · NASDAQ:NCNAUS$3.12M−US$21.37Mn/an/an/a0.1×n/a0.0×1.58
Revive Therapeutics Ltd. · CSE:RVVUS$3.10MUS$3.14Mn/an/an/an/an/an/a0.56
Skye Bioscience, Inc. · NASDAQ:SKYEUS$3.10M−US$1.71Mn/an/an/a2.3×n/a0.0×0.85
Median of the othersUS$3.19M−US$2.12M−0.8×0.7×−123.7%0.0×1.16

Team and board

OfficerRole
Chris KimCEO

Events

Next results
Nov 26, 2026 (expected)
QuarterResultsShare move
Q2 2026Aug 14, 2026−5.7%
Q3 2025Oct 6, 2025−8.7%
Q1 2025Apr 16, 2025
Q1 2023Apr 18, 2023−0.9%
Q3 2022Nov 21, 2022−0.1%
Q2 2022Aug 19, 2022−0.1%
Q1 2022Apr 18, 2022−0.2%
Q3 2021Nov 22, 2021−0.1%
Quarter to Jun 30, 2021Jul 22, 20210.0%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (June 2025)Investor deck22 slidesJun 24, 2025

Open Decks

Financings

RaiseDate
Public offering of common stock (or pre-funded warrants) and accompanying warrants
Announced: about US$4M · US$0.29 a share · Warrants at US$0.29 for 60 months · Maxim Group LLC
Dealers: Maxim Group LLC (lead)
Use of proceeds: Working capital, general corporate purposes and advancing the company's business objectives
Feb 17, 2026
Strategic investment of newly issued shares
Announced: US$30M
Buyers: Capital Trust Group Limited (USD 30,000,000 equity financing via subscription for newly issued shares)
Use of proceeds: Research and development of advanced immunotherapy assets
Oct 30, 2025
Not stated
Announced: up to US$500M · Digital Offering
Dealers: Digital Offering (lead)
Use of proceeds: Acquisition and long-term holding of BNB Coin through the planned American BNB Strategy subsidiary
Jul 28, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021
Revenue0000
Research and development02.69M3.76M1.85M3.80M
Selling, general and administrative2.97M645.0K1.06M856.0K197.0K
Operating income-2.97M-3.33M-2.59M-2.71M-2.53M
Depreciation and amortization1.83K01.00K
EBITDA-2.97M-3.33M-2.71M
Interest expense215.9K338.9K175.0K219.0K
Income before tax-10.2M-2.89M-1.19M-2.93M4.37M
Income tax18.8K34.0K539.8K
Net income-10.2M-3.55M-1.23M-2.93M4.37M
Earnings per share, basic-0.43-0.20-7.65-4.256.33
Earnings per share, diluted-0.43-0.20

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021
Cash and equivalents337.7K56.3K434.0K5.05M336.2K
Receivables6.46K945.0K100.0K1.26K
Current assets500.6K5.28M210.9K360.6K421.9K
Property, plant and equipment12.2K941
Total assets512.8K5.41M4.50M15.5M276.4M
Accounts payable582.2K1.48M933.0K508.0K419.0K
Current liabilities10.3M24.7M5.16M3.59M1.38M
Total debt1.44M5.12M16.1M16.5M90.0K
Total liabilities10.3M24.7M15.2M14.2M21.6M
Shareholders' equity-9.81M-19.3M-10.7M1.29M254.9M
Shares outstanding27.1M17.5M160.3K688.6K690.0K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021
Cash from operations-9.96M-1.45M-3.35M-869.0K-1.22M
Capital spending-13.1K0000
Free cash flow-9.98M-3.11M-3.35M-869.0K-1.22M
Cash from investing-788.1K-2.85M-819.0K264.0M-276.0M
Cash from financing11.0M3.92M-450.0K5.92M277.6M
Share buybacks-1.80M-10.7M-700.0K
Change in cash281.3K-378.1K-4.61M5.05M336.2K

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 18, 2026Current reportSEC
NT 10-Q · Late filing noticeNov 16, 2026Explanation requestSEC
8-K · Current reportNov 3, 2026Material contractSEC
8-K · Current reportSep 29, 2026Current reportSEC
8-K · Current reportAug 18, 2026Current reportSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
8-K · Current reportAug 4, 2026Meeting outcomeSEC
8-K · Current reportJul 29, 2026Current reportSEC
8-K · Current reportJul 24, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeJul 22, 2026Big-stake noticeSEC
All 111 filings
FilingDateTypeFiled with
4 · Change in ownershipJul 14, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 14, 2026Big-stake noticeSEC
DEF 14A · Proxy statementJul 13, 2026Meeting noticeSEC
4 · Change in ownershipJul 6, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 6, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 6, 2026Big-stake noticeSEC
8-K · Current reportJul 6, 2026Acquisition or disposalSEC
PRE 14A · Preliminary proxy statementJun 29, 2026Meeting noticeSEC
S-1 · Registration statementJun 23, 2026Offer documentSEC
DJun 18, 2026Other filingsSEC
8-K · Current reportJun 3, 2026Material contractSEC
424B3 · ProspectusJun 3, 2026Offer documentSEC
8-K · Current reportMay 27, 2026Current reportSEC
8-K · Current reportMay 20, 2026Material contractSEC
10-Q · Quarterly reportMay 15, 2026Quarterly reportSEC
10-K · Annual reportMar 31, 2026Annual reportSEC
8-K · Current reportMar 4, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeFeb 20, 2026Big-stake noticeSEC
8-K · Current reportFeb 18, 2026Material contractSEC
424B4 · ProspectusFeb 18, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveFeb 17, 2026Other filingsSEC
CORRESP · Letter to the SECFeb 11, 2026Other filingsSEC
CORRESP · Letter to the SECFeb 11, 2026Other filingsSEC
S-1 · Registration statementFeb 11, 2026Offer documentSEC
8-K · Current reportFeb 9, 2026Material contractSEC
8-K · Current reportJan 26, 2026Current reportSEC
UPLOAD · Letter from the SECJan 6, 2026Other filingsSEC
DRS · Draft registration statementDec 31, 2025Offer documentSEC
8-K · Current reportNov 25, 2025Current reportSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
10-Q · Quarterly reportOct 3, 2025Quarterly reportSEC
8-K · Current reportAug 25, 2025Current reportSEC
3 · Initial statement of ownershipAug 15, 2025Insider tradeSEC
NT 10-Q · Late filing noticeAug 14, 2025Explanation requestSEC
8-K · Current reportAug 14, 2025Current reportSEC
424B3 · ProspectusAug 13, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveAug 13, 2025Other filingsSEC
CORRESP · Letter to the SECAug 11, 2025Other filingsSEC
S-1/A · Registration statement, amendedJul 25, 2025Offer documentSEC
CORRESP · Letter to the SECJul 25, 2025Other filingsSEC
3 · Initial statement of ownershipJul 23, 2025Insider tradeSEC
3 · Initial statement of ownershipJul 21, 2025Insider tradeSEC
8-K · Current reportJul 17, 2025Material contractSEC
8-K · Current reportJul 11, 2025Management or board changeSEC
UPLOAD · Letter from the SECJul 3, 2025Other filingsSEC
8-K · Current reportJul 3, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeJun 27, 2025Big-stake noticeSEC
3 · Initial statement of ownershipJun 27, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJun 26, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJun 26, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJun 26, 2025Big-stake noticeSEC
S-1 · Registration statementJun 24, 2025Offer documentSEC
8-K · Current reportJun 24, 2025Current reportSEC
8-K · Current reportJun 24, 2025Current reportSEC
3 · Initial statement of ownershipJun 16, 2025Insider tradeSEC
8-K · Current reportJun 4, 2025Current reportSEC
10-Q · Quarterly reportMay 30, 2025Quarterly reportSEC
8-K/A · Current report, amendedMay 30, 2025Acquisition or disposalSEC
NT 10-Q · Late filing noticeMay 15, 2025Explanation requestSEC
SCHEDULE 13D · Big-stake noticeMay 8, 2025Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeMay 7, 2025Big-stake noticeSEC
8-K · Current reportMay 6, 2025Acquisition or disposalSEC
3 · Initial statement of ownershipMay 1, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 30, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 30, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 30, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 30, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 30, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 30, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 30, 2025Insider tradeSEC
8-K12BApr 30, 2025Other filingsSEC
424B3 · ProspectusFeb 7, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveFeb 7, 2025Other filingsSEC
CORRESP · Letter to the SECFeb 4, 2025Other filingsSEC
POS AM · Amendment to an effective registrationJan 27, 2025Offer documentSEC
CORRESP · Letter to the SECJan 27, 2025Other filingsSEC
UPLOAD · Letter from the SECJan 23, 2025Other filingsSEC
POS AM · Amendment to an effective registrationJan 16, 2025Offer documentSEC
CORRESP · Letter to the SECJan 15, 2025Other filingsSEC
UPLOAD · Letter from the SECDec 5, 2024Other filingsSEC
POS AM · Amendment to an effective registrationNov 8, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveAug 12, 2024Other filingsSEC
424B3 · ProspectusAug 9, 2024Offer documentSEC
CORRESP · Letter to the SECAug 9, 2024Other filingsSEC
S-4/A · Registration statement, amendedAug 9, 2024Offer documentSEC
S-4/A · Registration statement, amendedAug 8, 2024Offer documentSEC
CORRESP · Letter to the SECAug 8, 2024Other filingsSEC
UPLOAD · Letter from the SECAug 8, 2024Other filingsSEC
S-4/A · Registration statement, amendedAug 7, 2024Offer documentSEC
CORRESP · Letter to the SECAug 7, 2024Other filingsSEC
UPLOAD · Letter from the SECAug 5, 2024Other filingsSEC
S-4/A · Registration statement, amendedJul 25, 2024Offer documentSEC
CORRESP · Letter to the SECJul 25, 2024Other filingsSEC
UPLOAD · Letter from the SECJul 11, 2024Other filingsSEC
S-4/A · Registration statement, amendedJun 14, 2024Offer documentSEC
CORRESP · Letter to the SECJun 14, 2024Other filingsSEC
UPLOAD · Letter from the SECDec 4, 2023Other filingsSEC
CORRESP · Letter to the SECNov 8, 2023Other filingsSEC
S-4 · Registration statementNov 8, 2023Offer documentSEC
UPLOAD · Letter from the SECMay 30, 2023Other filingsSEC
DRS · Draft registration statementMay 1, 2023Offer documentSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Liminatus Pharma, Inc.’s releases · as of Feb 17, 2026

Common shares
1,343,207
Fully diluted
1,343,207

Fully diluted

LineShares
Common shares1,343,207

Share count over time

CountShares
Nov 22, 20261,343,207
Aug 18, 2026

Open Cap table

Shareholders

Funds

HolderSharesOf the companyValueAs of
Fidelity Extended Market Index Fund77,3000.12%US$12,677May 31, 2026
Vanguard Extended Market Index Fund50,4400.08%US$5,569Jun 30, 2026
Fidelity Nasdaq Composite Index Fund16,7700.02%US$2,750May 31, 2026
Fidelity Total Market Index Fund8,0960.01%US$1,328May 31, 2026
Fidelity Series Total Market Index Fund6,202<0.01%US$1,017May 31, 2026

Big stakes

StakeStakeSharesDateFiling
Iris Acquisition Holdings LLC26.50%6.9MApr 30, 2025Schedule 13D
KH Feelux Co., Ltd15.40%4MApr 30, 2025Schedule 13G
Valetudo Therapeutics LLC14.30%9.62MJul 2, 2026Schedule 13D
Ewon Comfortech Co., Ltd.10.90%5.5MJun 24, 2026Schedule 13G
Red Peony Association 1st5.70%1.47MApr 30, 2025Schedule 13G
Nongae Apple Association 1st5.70%1.47MApr 30, 2025Schedule 13G
Samda Biolab Co., Ltd.5.10%3.43MJul 2, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Beom Kyu ChoiChief Technology Officer · Apr 30, 2025 – Apr 30, 2025 · Past
Chris KimChief Executive Officer, Director · Since at least Apr 30, 2025
Chris KimCEO · Since at least Aug 24, 2026
Ji Yeon BaekDirector · Apr 30, 2025 – Apr 30, 2025 · Past
Richard JaiHwan BaekDirector · Since at least Jul 10, 2025
Sang-Jin LeeHead of Research & Development · Apr 30, 2025 – Apr 30, 2025 · Past

Open People

Log in to ask 6ix AI your own questions about Liminatus Pharma, Inc.